Arlene V. Drack
WASHINGTON — Visual benefits achieved after injection with Luxturna were not statistically significantly affected by patient age at time of treatment, according to a study presented at the American Association for Pediatric Ophthalmology and Strabismus meeting.
Arlene V. Drack, MD, reported on the 3-year results of a phase 3 trial of Luxturna (voretigene neparvovec-rzyl, Spark Therapeutics) in RPE65 mutation-associated inherited retinal disease undertaken at Children’s Hospital of Philadelphia and University of Iowa.
“For every two patients enrolled to
Uncategorized